NeuroBo Pharmaceuticals IncNASDAQ:NRBO
- LAST PRICE3.4600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.2600/ 10
- Ask / Lots3.8800/ 1
- Open / Previous Close3.6900 / 3.4600
- Day Range
- 52 Week Range
- Volume11,485
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRBO |
|---|---|---|
| 09:32 ET | 198 | 3.69 |
| 09:52 ET | 200 | 3.68 |
| 11:26 ET | 150 | 3.5065 |
| 12:20 ET | 500 | 3.54 |
| 12:27 ET | 151 | 3.55 |
| 02:26 ET | 100 | 3.54 |
| 02:27 ET | 229 | 3.56 |
| 02:54 ET | 1650 | 3.6 |
| 03:03 ET | 220 | 3.53 |
| 03:43 ET | 157 | 3.53 |
| 03:45 ET | 446 | 3.46 |
Yesterday
Apr 1, 2024
Mar 28, 2024
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update, from 8:01AM ET on Thursday Mar 28, 2024 by Dow Jones
8:01AM ET on Thursday Mar 28, 2024 by Dow JonesPress Release: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update, from 8:01AM ET on Thursday Mar 28, 2024 by Dow Jones
8:01AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NeuroBo Pharmaceuticals Inc | 16.7M | -1.3x | --- |
Oncotelic Therapeutics Inc | 16.4M | -1.3x | --- |
Nascent Biotech Inc | 16.2M | -6.5x | --- |
Minerva Neurosciences Inc | 17.5M | -0.5x | --- |
Curative Biotechnology Inc | 17.6M | -2.5x | --- |
Purple Biotech Ltd | 15.5M | -0.5x | --- |
Company Information
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
Contact Information
- Headquarters
- 545 Concord Avenue, Suite 210CAMBRIDGE, MA, United States 02138
- Phone
- 857-702-9600
- Fax
- 734-293-0444
Executives
- Independent Chairman of the Board
- Andrew Koven
- President, Chief Executive Officer, Director
- Hyung Kim
- Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
- Marshall Woodworth
- Independent Director
- Indep Glickman
- Independent Director
- Mark Glickman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.25 |
EPS | $-2.71 |
Book Value | $3.40 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
